All In Biotech

Drug Trial Radar · NCT05964790

Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia

A Phase Ⅰb/Ⅱ, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10380 in Chinese Adults With Schizophrenia.

Last checked: Nov 19, 2026Latest source record: Jul 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 112 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

112

Planned (sponsor's estimate)

Start

Jul 30, 2023

Primary completion

Jun 30, 2024

Study completion Dec 30, 2024

Sponsor

Sponsor type
Industry
First posted
Jul 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-10380 relative to placebo for the treatment of participants with schizophrenia.

Conditions

  • Schizophrenia

Interventions

  • HS-10380Drug

    Participants in arm HS-10380 will receiving multiple ascending doses of HS-10380 (1.5 mg initial dose) orally once daily for 28 days

  • PlaceboDrug

    Participants in arm Placebo will receiving multiple ascending doses of Placebo matching HS-10380 (1.5 mg initial dose) orally once daily for 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose escalation cohorts: Incidence and severity of adverse events(AE) ,serious AEs and AE leading to withdrawal from treatment.Time frame: Baseline to Day 43
  2. Dose escalation cohorts: Changes from baseline in complete blood count (CBC).Time frame: Baseline to Day 36
  3. Dose escalation cohorts: Changes from baseline in urinalysis.Time frame: Baseline to Day 36
  4. Dose escalation cohorts: Changes from baseline in blood biochemistry test.Time frame: Baseline to Day 36
  5. Dose escalation cohorts: Changes from baseline in coagulation function test.Time frame: Baseline to Day 36
  6. Dose escalation cohorts: Changes from baseline in thyroid function test.Time frame: Baseline to Day 36
  7. Dose escalation cohorts: Changes from baseline in serum prolactin.Time frame: Baseline to Day 36
  8. Dose escalation cohorts: Changes from baseline in blood pressure (BP).Time frame: Baseline to Day 36
  9. Dose escalation cohorts: Changes from baseline in pulse rate.Time frame: Baseline to Day 36
  10. Dose escalation cohorts: Changes from baseline in body temperature.Time frame: Baseline to Day 36
  11. Dose escalation cohorts: Change from baseline in body weightTime frame: Baseline to Day 29
  12. Dose escalation cohorts: Change from baseline in Electrocardiogram (ECG)Time frame: Baseline to Day 36
  13. Dose escalation cohorts: Change from baseline in Simpson-Angus Scale (SAS)Time frame: Baseline to Day 36
  14. Change from baseline in Abnormal Involuntary Movement Scale (AIMS)Time frame: Baseline to Day 36
  15. Dose escalation cohorts: Change from baseline in Barnes Akathisia Rating ScaleTime frame: Baseline to Day 36
  16. Dose escalation cohorts: Change from Baseline in Columbia - Suicide Severity Rating Scale (C-SSRS)Time frame: Baseline to Day 36
  17. Expansion cohorts: Change from Baseline in Positive and Negative Syndrome Scale (PANSS)Time frame: Baseline to Day 28
  18. Expansion cohorts: Positive and Negative Syndrome Scale (PANSS) Response at Week 4, Defined as a 20% or Greater Improvement from Baseline in PANSS Total ScoreTime frame: Baseline to Day 28
  19. Expansion cohorts: Change from Baseline in Clinical Global Impression-Severity (CGI-S)Time frame: Baseline to Day 28

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.